PT  - JOURNAL ARTICLE
AU  - Pana, Tiberiu A
AU  - Mohamed, Mohamed O
AU  - Mamas, Mamas A
AU  - Myint, Phyo K
TI  - Prognosis of Acute Ischaemic Stroke in Cancer Patients: A National Inpatient Sample Study
AID  - 10.1101/2021.03.09.21253211
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.09.21253211
4099  - http://medrxiv.org/content/early/2021/03/11/2021.03.09.21253211.short
4100  - http://medrxiv.org/content/early/2021/03/11/2021.03.09.21253211.full
AB  - Background and Purpose Whilst cancer is a risk factor for acute ischaemic stroke (AIS), its impact on AIS prognosis between metastatic and non-metastatic (MC and NMC) disease is poorly understood. Furthermore, the receipt of intravenous thrombolysis (IVT) and endovascular thrombectomy (ET) and their outcomes is poorly researched.Methods AIS admissions from the National Inpatient Sample (NIS) were included (October 2015-December 2017). Multivariable logistic regressions adjusting for a wide range of confounders analysed the relationship between NMC and MC and AIS in-hospital outcomes (mortality, prolonged hospitalisation >4 days and routine home discharge). Interaction terms with IVT and ET were also computed to explore their impact amongst cancer patients.Results 221,249 records representative of 1,106,045 admissions were included. There were 38,855 (3.51%) patients with co-morbid cancers: NMC=53.78% and MC=46.22%. NMC was associated with 23% increased odds of in-hospital mortality (odds ratio (95% confidence interval) = 1.23 (1.07-1.42)), which was mainly driven by pancreatic and respiratory cancers. This association was entirely offset by both IVT and ET. MC was associated with 2-fold increased odds of in-hospital mortality (2.16 (1.90-2.45)), which was mainly driven by respiratory, pancreatic and colorectal cancers. This association was only offset by ET. Both NMC and MC were significantly associated with prolonged hospitalisation and decreased odds of routine discharge.Conclusions Cancer patients are at higher odds of acute adverse outcomes after AIS and warrant robust primary prevention. IVT and ET improve these outcomes and should thus be offered routinely unless otherwise contraindicated in this group of stroke patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study has received no specific funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As the NIS is publicly available and contains no patient identifiable information, no ethical approval was needed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.NON-STANDARD ABBREVIATIONS AND ACRONYMSAISAcute Ischaemic StrokeETEndovascular ThrombectomyHCUPHealthcare Cost and Utilisation ProjectICD-19International Classification of Disease – tenth editionIVTIntravenous ThrombolysisLoSLength of stayMCMetastatic CancerNISNational Inpatient SampleNMCNon-metastatic CancerUSUnited States;